Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
McKinsey
Citi
Julphar
Cantor Fitzgerald
Deloitte
Daiichi Sankyo
Boehringer Ingelheim

Generated: January 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208705

« Back to Dashboard

NDA 208705 describes FENOFIBRIC ACID, which is a drug marketed by Actavis Elizabeth, Alembic Pharms Ltd, Anchen Pharms, Impax Labs Inc, Lupin Ltd, and Mylan Pharms Inc, and is included in six NDAs. It is available from seven suppliers. Additional details are available on the FENOFIBRIC ACID profile page.

The generic ingredient in FENOFIBRIC ACID is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
Summary for 208705
Tradename:FENOFIBRIC ACID
Applicant:Alembic Pharms Ltd
Ingredient:choline fenofibrate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 208705
Suppliers and Packaging for NDA: 208705
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 208705 ANDA Alembic Pharmaceuticals Limited 46708-244 46708-244-30 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (46708-244-30)
FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 208705 ANDA Alembic Pharmaceuticals Limited 46708-244 46708-244-90 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (46708-244-90)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 45MG FENOFIBRIC ACID
Approval Date:May 12, 2017TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 135MG FENOFIBRIC ACID
Approval Date:May 12, 2017TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Chubb
Fuji
Argus Health
Dow
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.